Biopharmaceutical company Wilson Therapeutics AB (STO:WTX) announced on Thursday that members of its nomination committee, for the Annual General Meeting 2018, are Andrew Kay, chairman of the company's board of directors; Staffan Lindstrand, representing HealthCap; Sarah Shackelton, representing Abingworth and Thomas Casdagli, representing MVM.

This nomination committee has appointed Shackelton as its chairman.

Reportedly, in accordance with the decision of the Annual General Meeting on 17 May 2017, the company's nomination committee for the AGM 2018 shall comprise the chairman of the board of directors and one representative for each of the three largest shareholders based on ownership of the company, as on the end of September 2017.

Wilson Therapeutics develops novel therapies for patients with rare copper-mediated disorders.